Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Blinatumomab-Related ICANS Symptoms More Prevalent Than Prior Reports

April 11, 2025
By Russ Conroy
Fact checked by" Roman Fabbricatore
News
Article
Conference|Oncology Nursing Society’s Annual Meeting (ONS)

An objective assessment tool like the ICE Score may standardize grading of neurotoxicity associated with newer bispecific antibodies in hematologic cancer.

“Utilizing an objective assessment tool, such as the Immune Effector Cell Encephalopathy [ICE] Score, would standardize nursing assessment and grading of neurotoxicity like newer bispecific antibodies and potentially prevent treatment interruptions due to more mild symptoms," according to study author Jessica [RC1] Miles, MS, RN, CNS, AOCNS, BMTCN.

“Utilizing an objective assessment tool, such as the Immune Effector Cell Encephalopathy [ICE] Score, would standardize nursing assessment and grading of neurotoxicity like newer bispecific antibodies and potentially prevent treatment interruptions due to more mild symptoms," according to study author Jessica [RC1] Miles, MS, RN, CNS, AOCNS, BMTCN.

The incidence of symptoms consistent with immune effector cell-associated neurotoxicity syndrome (ICANS) following treatment with blinatumomab (Blincyto) was found to be higher than what prior reports demonstrated, according to findings from a poster presentation at the 50th Annual Oncology Nursing Society Conference.1

Of 28 patients who received blinatumomab, 57% experienced any neurotoxicity, and 46% had any aphasia and/or encephalopathy. Approximately 25% of aphasia and/or encephalopathy events were grade 3.

Data showed that the most common neurotoxicity symptoms included headache (69%), encephalopathy (69%), tremors (63%), and aphasia (38%). Additionally, dizziness and paresthesia occurred in 19% and 13% of patients, respectively.

Regarding toxicity intervention strategies, investigators stopped blinatumomab infusion for an equal proportion of patients with grade 2 and grade 3 events. However, initiating prophylaxis with steroids was more common for patients with grade 2 toxicities compared with those who had grade 3 events.

“Our study population experienced a higher rate of symptoms consistent with ICANS compared to what has been reported. Implementation of interventions was not consistent between grade 2 and grade 3 symptoms,” lead study author Jessica Miles, MS, RN, CNS, AOCNS, BMTCN, a clinical nurse specialist in oncology at University of California Davis Medical Center, wrote with coauthors.1 “Utilizing an objective assessment tool, such as the Immune Effector Cell Encephalopathy [ICE] Score, would standardize nursing assessment and grading of neurotoxicity like newer bispecific antibodies and potentially prevent treatment interruptions due to more mild symptoms.”

Regarding the study’s rationale, investigators noted that bispecific antibodies like blinatumomab are known to cause ICANS, which is graded using the ICE Score as a screening and diagnosis standard. ICANS, however, was defined following the approval of blinatumomab and not included in studies assessing treatment with the bispecific antibody.

According to the 2024 prescribing information for blinatumomab, the rate of signs and symptoms consistent with ICANS was 7.5% in clinical trials evaluating the agent.2 Additionally, the label recommends withholding treatment with blinatumomab in the event of grade 3 neurotoxicity.

Based on this context, investigators aimed to evaluate the incidence and symptoms of neurotoxicity related to blinatumomab while identifying patterns in interventions for mitigating these toxicities. As part of a retrospective cohort study, investigators assessed adult patients who underwent treatment with blinatumomab between 2020 and 2023. Data evaluation involved an electronic record review, and investigators used descriptive statistics to analyze patient outcomes.

According to the prescribing information for blinatumomab, the FDA initially approved the agent for intravenous use in 2014. The anti-CD19 T-cell engager is indicated for use in adult and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) expression of at least 0.1% and those with relapsed/refractory CD19-positive B-cell precursor ALL.

Blinatumomab is contraindicated for patients with known hypersensitivity to the agent or any of its components. Additionally, the labelling includes warnings and precautions for the possibility of cytokine release syndrome, ICANS, infections, tumor lysis syndrome, neutropenia, elevated pancreatitis, leukoencephalopathy, and embryo-fetal toxicity.

Investigators assessed the efficacy of blinatumomab for patients with MRD-positive B-cell precursor ALL in the BLAST study (NCT01207388). Overall, 70 patients (81.4%; 95% CI, 71.6%-89.0%) achieved undetectable MRD, and the median hematological relapse-free survival was 22.3 months.

The open-label TOWER study (NCT02013167) evaluated blinatumomab vs standard-of-care chemotherapy among patients with relapsed/refractory B-cell precursor ALL.Data showed a median overall survival of 7.7 months (95% CI, 5.6-9.6) with blinatumomab vs 4.0 months (95% CI, 2.9-5.3) with chemotherapy (HR, 0.71; 95% CI, 0.55-0.93; P = .012).

References

  1. Miles J. Unraveling blinatumomab-associated neurotoxicity: incidence and interventions. Presented at the 50th Annual Oncology Nursing Society Conference; April 9-13, 2025; Denver, CO. Poster RS104.
  2. BLINCYTO® (blinatumomab) for injection, for intravenous use. Prescribing information. FDA; 2024. Accessed April 8, 2025. https://tinyurl.com/3y9fx5ms
Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Related Content
Advertisement

From breast cancer to head and neck tumors, the 2025 ASCO Annual Meeting may feature a wide range of practice-changing data across cancer care.

ASCO 2025: The Presentations That May Shift the Cancer Care Paradigm

Russ Conroy
May 23rd 2025
Article

From breast cancer to head and neck tumors, the 2025 ASCO Annual Meeting may feature a wide range of practice-changing data across cancer care.


Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.


Final OS data from INAVO120 demonstrate, for the first time, a significant OS improvement with a PI3K-targeted agent in this breast cancer population.

Inavolisib Combo Significantly Extends Survival in PIK3CA+ Breast Cancer

Caroline Seymour
May 22nd 2025
Article

Final OS data from INAVO120 demonstrate, for the first time, a significant OS improvement with a PI3K-targeted agent in this breast cancer population.


Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Rahul Banerjee, MD, FACP;Shernan Holtan, MD
March 3rd 2025
Podcast

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.


65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population

65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population

Allen Gee;Grace Oh;June Lee
May 12th 2025
Article

67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery

67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery

Ken Weixing Ho;Nicholas Holford;Rathi Ramakrishnan;Patriek Jurrius;Sarah Pinder;Arnie Purushotham;Daniel Leff
May 11th 2025
Article
Related Content
Advertisement

From breast cancer to head and neck tumors, the 2025 ASCO Annual Meeting may feature a wide range of practice-changing data across cancer care.

ASCO 2025: The Presentations That May Shift the Cancer Care Paradigm

Russ Conroy
May 23rd 2025
Article

From breast cancer to head and neck tumors, the 2025 ASCO Annual Meeting may feature a wide range of practice-changing data across cancer care.


Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.


Final OS data from INAVO120 demonstrate, for the first time, a significant OS improvement with a PI3K-targeted agent in this breast cancer population.

Inavolisib Combo Significantly Extends Survival in PIK3CA+ Breast Cancer

Caroline Seymour
May 22nd 2025
Article

Final OS data from INAVO120 demonstrate, for the first time, a significant OS improvement with a PI3K-targeted agent in this breast cancer population.


Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Rahul Banerjee, MD, FACP;Shernan Holtan, MD
March 3rd 2025
Podcast

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.


65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population

65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population

Allen Gee;Grace Oh;June Lee
May 12th 2025
Article

67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery

67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery

Ken Weixing Ho;Nicholas Holford;Rathi Ramakrishnan;Patriek Jurrius;Sarah Pinder;Arnie Purushotham;Daniel Leff
May 11th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.